REPLIMUNE GROUP, INC. (REPL) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $4.26M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $4.26M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $4.26M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 146.80M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 4.26M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 455.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $3.27M |
| Finance lease obligations | $24.59M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.26M | (m) | (m) | (m) | $146.80M | (m) | (m) | (m) | $455.00K | (m) |
| 2026-03-31 | (m) | $6.67M | (m) | (m) | (m) | $166.23M | (m) | (m) | (m) | $455.00K | (m) |
| 2025-12-31 | (m) | $5.65M | (m) | (m) | (m) | $123.05M | (m) | (m) | (m) | $693.00K | (m) |
| 2025-09-30 | (m) | $6.40M | (m) | (m) | (m) | $126.11M | (m) | (m) | (m) | $941.00K | (m) |
| 2025-06-30 | (m) | $15.48M | (m) | (m) | (m) | $132.79M | (m) | (m) | (m) | $941.00K | (m) |
| 2025-03-31 | (m) | $12.46M | (m) | (m) | (m) | $135.49M | (m) | (m) | (m) | $941.00K | (m) |
| 2024-12-31 | (m) | $7.19M | (m) | (m) | (m) | $121.25M | (m) | (m) | (m) | $1.27M | (m) |
| 2024-09-30 | (m) | $8.41M | (m) | (m) | (m) | $116.74M | (m) | (m) | (m) | $786.00K | (m) |
| 2024-06-30 | (m) | $864.00K | (m) | (m) | (m) | $108.51M | (m) | (m) | (m) | $786.00K | (m) |
| 2024-03-31 | (m) | $2.58M | (m) | (m) | (m) | $113.21M | (m) | (m) | (m) | $786.00K | (m) |
| 2023-12-31 | (m) | $3.90M | (m) | (m) | (m) | $111.39M | (m) | (m) | (m) | $793.00K | (m) |
| 2023-09-30 | (m) | $4.37M | (m) | (m) | (m) | $97.23M | (m) | (m) | (m) | $472.00K | (m) |
| 2023-06-30 | (m) | $4.88M | (m) | (m) | (m) | $89.86M | (m) | (m) | (m) | $578.00K | (m) |
| 2023-03-31 | (m) | $5.36M | (m) | (m) | (m) | $91.30M | (m) | (m) | (m) | $472.00K | (m) |
| 2022-12-31 | (m) | $3.65M | (m) | (m) | (m) | $83.20M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.00M | (m) | (m) | (m) | $52.02M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $4.48M | (m) | (m) | (m) | $49.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $3.73M | (m) | (m) | (m) | $49.96M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.92M | (m) | (m) | (m) | $47.77M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.15M | (m) | (m) | (m) | $46.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.38M | (m) | (m) | (m) | $44.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.35M | (m) | (m) | (m) | $44.37M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.35M | (m) | (m) | (m) | $43.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.37M | (m) | (m) | (m) | $52.85M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.48M | (m) | (m) | (m) | $51.77M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.43M | (m) | (m) | (m) | $50.38M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.26M | (m) | (m) | (m) | $52.86M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $7.96M | (m) | (m) | (m) | $30.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $10.83M | (m) | (m) | (m) | $13.39M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $7.08M | (m) | (m) | (m) | $16.47M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $1.50M | (m) | (m) | (m) | $8.95M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.07M | (m) | (m) | (m) | $3.78M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.85M | (m) | (m) | (m) | $11.63M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.99M | (m) | (m) | (m) | $6.86M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |